Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1422-1428

  Visscher, Henk ^a   Ross, Colin J D ^a   Rassekh, S Rod ^a   Barhdadi, Amina ^b   Dubé, Marie Pierre ^b   Al Saloos, Hesham ^a   Sandor, George S ^a   Caron, Huib N ^e   Van Dalen, Elvira C ^e   Kremer, Leontien C ^e   Van Der Pal, Helena J ^e   Brown, Andrew M K ^b,c   Rogers, Paul C ^a   Phillips, Michael S ^b,c   Rieder, Michael J ^d   Carleton, Bruce C ^a   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c Beaulieu Saucier Pharmacogenomics Centre   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABCB4 PROTEIN; ABCC1 PROTEIN; DAUNORUBICIN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; CARRIER PROTEIN; CIF NUCLEOSIDE TRANSPORTER;

ACCURACY; ADOLESCENT; ARTICLE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG TRANSFORMATION; FEMALE; GENE; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PHARMACOGENOMICS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; AGE; BIOTRANSFORMATION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HEART DISEASE; KAPLAN MEIER METHOD; METABOLISM; MULTICENTER STUDY; NEOPLASM; NEWBORN; PHARMACOGENETICS; PHENOTYPE; RISK; RISK ASSESSMENT;

ADOLESCENT; AGE FACTORS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOTRANSFORMATION; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEART DISEASES; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; NETHERLANDS; ODDS RATIO; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS;

EID: 84863001655     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.3467     Document Type: Article

References (46)

1. Lipshultz SE, Alvarez JA, Scully RE: Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525-533, 2008 (Pubitemid 351441417)
2. Altekruse SF, Kosary CL, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2007. Bethesda, MD, National Cancer Institute, 2010
3. Kremer LC, van der Pal HJ, Offringa M, et al: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol 13:819-829, 2002 (Pubitemid 34752678)
4. van der Pal HJ, van Dalen EC, Hauptmann M, et al: Cardiac function in 5-year survivors of childhood cancer: A long-term follow-up study. Arch Intern Med 170:1247-1255, 2010
5. Lefrak EA, Pitha J, Rosenheim S, et al: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973
6. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979 (Pubitemid 10218041)
7. Kremer LC, van Dalen EC, Offringa M, et al: Frequency and risk factors of anthracycline-induced clinical heart failure in children: A systematic review. Ann Oncol 13:503-512, 2002 (Pubitemid 34461132)
8. Felker GM, Thompson RE, Hare JM, et al: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084, 2000 (Pubitemid 30207690)
9. Wouters KA, Kremer LC, Miller TL, et al: Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br J Haematol 131:561-578, 2005 (Pubitemid 43899624)
10. Wojnowski L, Kulle B, Schirmer M, et al: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754-3762, 2005 (Pubitemid 43739516)
11. Simunek T, Sterba M, Popelova O, et al: Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154-171, 2009
12. Lipshultz SE, Adams MJ: Cardiotoxicity after childhood cancer: Beginning with the end in mind. J Clin Oncol 28:1276-1281, 2010
13. Tukenova M, Guibout C, Oberlin O, et al: Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308-1315, 2010
14. Gianni L, Herman EH, Lipshultz SE, et al: Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 26:3777-3784, 2008
15. Rossi D, Rasi S, Franceschetti S, et al: Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23:1118-1126, 2009
16. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al: Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789-2795, 2008 (Pubitemid 351969225)
17. Rajić V, Aplenc R, Debeljak M, et al: Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 50:1693-1698, 2009
18. Carleton B, Poole R, Smith M, et al: Adverse drug reaction active surveillance: Developing a national network in Canada's children's hospitals. Pharmacoepidemiol Drug Saf 18:713-721, 2009
19. van Dalen EC, van der Pal HJ, Kok WE, et al: Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. Eur J Cancer 42:3191-3198, 2006 (Pubitemid 44872945)
20. National Cancer Institute: Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 3. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
21. Altman AJ (ed): Supportive Care of Children With Cancer: Current Therapy and Guidelines From the Children's Oncology Group (ed 3). Baltimore, MD, Johns Hopkins University Press, 2004
22. Purcell S, Neale B, Todd-Brown K, et al: PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575, 2007 (Pubitemid 47330214)
23. Gao X, Starmer J, Martin ER: A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 32:361-369, 2008 (Pubitemid 351656307)
24. Price AL, Patterson NJ, Plenge RM, et al: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904-909, 2006 (Pubitemid 44141658)
25. Visscher H, Ross CJ, Dube MP, et al: Application of principal component analysis to pharmacogenomic studies in Canada. Pharmacogenomics J 9:362-372, 2009
26. Kraft P, Wacholder S, Cornelis MC, et al: Beyond odds ratios: Communicating disease risk based on genetic profiles. Nat Rev Genet 10:264-269, 2009
27. Ritzel MW, Ng AM, Yao SY, et al: Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276:2914-2927, 2001
28. Badagnani I, Chan W, Castro RA, et al: Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J 5:157-165, 2005 (Pubitemid 40852217)
29. Damaraju S, Zhang J, Visser F, et al: Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenet Genomics 15:173-182, 2005 (Pubitemid 40569904)
30. Zeller T, Wild P, Szymczak S, et al: Genetics and beyond: The transcriptome of human monocytes and disease susceptibility. PLoS One 5:e10693, 2010
31. Okazaki T, Javle M, Tanaka M, et al: Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 16:320-329, 2010
32. Nagasawa K, Nagai K, Ohnishi N, et al: Contribution of specific transport systems to anthracycline transport in tumor and normal cells. Curr Drug Metab 2:355-366, 2001 (Pubitemid 33133980)
33. Innocenti F, Iyer L, Ramirez J, et al: Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692, 2001 (Pubitemid 32374570)
34. van Asperen J, van Tellingen O, Tijssen F, et al: Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 79:108-113, 1999 (Pubitemid 28566934)
35. Smith AJ, van Helvoort A, van Meer G, et al: MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275:23530-23539, 2000 (Pubitemid 30624635)
36. Zaman GJ, Flens MJ, van Leusden MR, et al: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A 91:8822-8826, 1994
37. Riggs CE Jr, Benjamin RS, Serpick AA, et al: Bilary disposition of adriamycin. Clin Pharmacol Ther 22:234-241, 1977
38. Behnia K, Boroujerdi M: Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model. Cancer Chemother Pharmacol 41:370-376, 1998 (Pubitemid 28095752)
39. Dawson PA, Haywood J, Craddock AL, et al: Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 278:33920-33927, 2003 (Pubitemid 37553226)
40. Krishnaswamy S, Hao Q, Al-Rohaimi A, et al: UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 313:1340-1346, 2005 (Pubitemid 40727040)
41. Andrews PA, Brenner DE, Chou FT, et al: Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos 8:152-156, 1980 (Pubitemid 10121053)
42. Levitt G, Anazodo A, Burch M, et al: Cardiac or cardiopulmonary transplantation in childhood cancer survivors: An increasing need? Eur J Cancer 45:3027-3034, 2009
43. van Dalen EC, Caron HN, Dickinson HO, et al: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2:CD003917, 2008
44. Lipshultz SE, Scully RE, Lipsitz SR, et al: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961, 2010
45. Lipshultz SE, Rifai N, Dalton VM, et al: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145-153, 2004 (Pubitemid 38886649)
46. Fryer C: Late effects in childhood cancer survivors: A review with a framing effect bias? Pediatr Blood Cancer [epub ahead of print on January 19, 2011]